2024年10月7日,嘉和生物(06998.HK)发布重磅交易公告,宣布其将与国内领先的集研产销能力的综合性药企——亿腾医药达成战略性合并。此次亿腾和嘉和的合并标志着两家公司在中国医药市场的强强联手,推动双方资源和技术的深度整合,进一步提升中国创新药物研发和商业化领域的竞争力。本次交易中,嘉和生物作价1.97亿美元、亿腾医药作价6.77亿美元。嘉和生物采用新发方式向亿腾医药的现有股东发行新股,以...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.